
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SNY | NASDAQ | USD | Real-time | |
SANp | BATS Europe | EUR | Delayed | |
0O59 | London | EUR | Real-time | |
SNYN | Mexico | MXN | Delayed | |
SANF | Milan | EUR | Real-time | |
SASY | Frankfurt | EUR | Delayed | |
SASY | Xetra | EUR | Delayed | |
SASY | TradeGate | EUR | Delayed | |
SASY | Paris | EUR | Real-time |
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) climbed by more than 5%, as analysts noted the "blockbuster potential" of the French drugmaker's asthma and eczema medicine Dupixent...
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review